Lung cancer has become a chronic disease Currently, the overall 5-year survival rate after diagnosis of lung cancer in the United States is about 15.8%, while the 1-year survival rate for stage IV patients with platinum-containing combination chemotherapy is about 30-40%. 25% of early-stage lung cancer patients can be clinically cured through a combination of treatments based on surgical procedures. For stage III/IV lung cancer that cannot be surgically resected, chemoradiotherapy-based combination therapy can significantly improve the 5-year survival of patients. For patients with effective targeted therapy, targeted therapy can significantly prolong the survival period of lung cancer patients, improve the quality of life and “live with tumor” for a long time, so lung cancer has become a chronic disease. This stage IV lung cancer patient has been living well in long-term treatment for 8 years since the onset of the disease. A large number of clinical trials at home and abroad have proved that for stage III/IV lung cancer patients, comprehensive treatment based on chemotherapy and radiotherapy can significantly increase their 5-year survival and improve their quality of life. In the past, it was advocated to stop chemotherapy after 4-6 cycles of chemotherapy for patients with effective or stable chemotherapy, and then switch to second-line treatment after their progression. 2011 NCCN recommended maintenance therapy as an option for non-small cell lung cancer after effective chemotherapy. This patient was treated with 21 chemotherapies, including 16 cycles of Bemetrexed + Oxaliplatin, and 12 cycles of maintenance therapy over a 4-year period. The principle of maintenance therapy is to choose a drug that is effective in previous treatments and has few side effects. It is the low side effects and the good tolerability of Bemetrexed that allow the patient to use it for a long time and persist until the disease progresses. Currently, Bemetrexed has been included in the indications for lung cancer maintenance therapy. The principle of individualization cannot be neglected in tumor treatment Tumor patients’ choice of treatment plan should be different due to the differences in pathological type, tumor genes, physical condition and economic status, etc. The wishes of patients and their families should be fully respected in the subsequent treatment selection, and their physical and economic ability should be fully considered. We should pay attention to patients in treatment, not only to keep them alive, but also to make them live with dignity and quality.